Skip to main content

Vasculitis

ICYMI: EGPA in 2025

Formerly classified as an ANCA-associated vasculitis, EGPA is both most commonly ANCA negative and clinically different to the other two ANCA-associated vasculitis conditions, GPA and MPA. The management of EGPA has frequently fallen into the trap of being copied from its more common and well-

Read Article
A Review of Intracranial GCA A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes. https://t.co/NkN4gfcq3n
Dr. John Cush @RheumNow( View Tweet )

PCR: Prevalence, Cost, & Risk (6.27.2025)

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Read Article

A Review of Intracranial GCA

A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.

A systematic review included 102

Read Article
EULAR 2025 – Day 3 Report Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treating high-risk pre-clinical RA, and EULAR Recommendations on ILD treatment, physical activity for arthritis, the EULAR disease activity score for antiphospholipid https://t.co/FAaj443wPX
Dr. John Cush @RheumNow( View Tweet )

Add-on certolizumab in pregnant women with APS

Women with antiphospholipid syndrome and lupus anti-coagulant are at high risk of developing adverse pregnancy outcomes (APO). Usual care includes low molecular weight heparin (LMWH) and low dose aspirin (LDA). Despite these therapies, APO have been reported up to 40%. An important

Read Article
Management of AAV: 1.High dose GC f/b reduced dose taper ‼️caution in pts w/severe renal dz and RTX induction. 2. RTX effective for induction and maintenance, best for relapses. 3.PLEX: in RPGN pts if accesible ⚠️ risk for infection. 4.Avacopan: for faster GC weaning. No https://t.co/kfZ4gM38KG
Adela Castro @AdelaCastro222( View Tweet )
Pearls on EGPA: 1. GC are mainstay for mild dz 2. Organ threatening/relapsing➡️CYP (RTX alternative) 3. W/o organ threatening➡️ anti-IL-5/IL-5R. 4. IL5i are less effective for ENT 5. Consider sx for nasal polyps. #EULAR2025 @RheumNow https://t.co/zoJEWxafsN
Adela Castro @AdelaCastro222( View Tweet )
Manifestations of relapsing polychondritis @Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#ClinicalPearls For #cartilage #swelling in #relapsing #polychrondritis Ask for #pics #Levamisole in #cocaine #infection - uncommon - from piercing Acute #bacterial v chronic #lymphoma #malignancy #vasculitis #Trauma Hx, duration, fever can be helpful #EULAR2025 @RheumNow https://t.co/X2b6VHYsYa
Janet Pope @Janetbirdope( View Tweet )
#Relapsing_Polychondritis Main differential diagnosis is GPA 🔺️No ANCA and no renal involvement in relapsing polychondritis @Lupusreference #EULAR2025 @RheumNow https://t.co/QUJZ3EDjj3
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Tips for Dx RP: 1. Suspect the dx and recognize chondritis. 2. Rule out mimickers 3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA) 4. CV, heme, derm manifestations 🧐VEXAS. 5. biopsy not useful unless ≠ from GCA. Fantastic session by @Lupusreference https://t.co/W4DgfeRULF
Adela Castro @AdelaCastro222( View Tweet )
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Rheumatoid vasculitis: what to look for and how to find it #EULAR2025 @AshimaMakol @RheumNow https://t.co/ZCUXgOr1dH
David Liew @drdavidliew( View Tweet )
How to treat rheumatoid vasculitis #EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx
David Liew @drdavidliew( View Tweet )
What kills in GCA? Greek national prospective cohort, small numbers and no doubt some channeling bias, but: Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality. With new options, all GCA pts should be on something #EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF
David Liew @drdavidliew( View Tweet )

Safety of Recombinant Zoster Vaccine in Rheumatic Patients

EurekAlert!

New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory rheumatic and

Read Article
#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ⬇️BVAS over 1 yr in all groups #GPA #MPA #eGPA 5yr survival not = over time ⬆️survival in eGPA & GPA vs MPA #POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS
Janet Pope @Janetbirdope( View Tweet )

EULAR 2025 – Day 2 Report

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few

Read Article
Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ
Dr. John Cush @RheumNow( View Tweet )

EULAR 2025 - Day 1 Report

Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article

Secukinumab Use in Refractory Giant Cell Arteritis

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger phase 3 trial, there is a 6 patient case series also suggesting

Read Article

HLA-B27 Testing in Practice

Analysis of testing for human leukocyte antigen B27 (HLA-B27) in a teaching center shows HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications and primarily as a screening test. 

Data

Read Article
Single center study of 1538 #SLE pts found 2.2% w/ lupus mesenteric vasculitis (LMV) - 39 LMV episodes in 31 pts - 2/3 had Nausea, vomiting, diarrhea & abdominal pain (~15% peritoneal irritation) & had active Dz (renal, Skin, Heme). LMV responded to steroids & https://t.co/vXCpbiC60P
Dr. John Cush @RheumNow( View Tweet )
Belimumab in SLE with Mucocutaneous or Vasculitis Findings A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care. https://t.co/BlYWKLJPdb

Dr. John Cush @RheumNow( View Tweet )

×